Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma

NCT00106431 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00106431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00106431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2005
Completion date
December 1, 2008
Enrollment
102 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma